
Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...

LanzaTech and Plastipak produce greener PET
The PPKNatura resin might safe up to 30% carbon emissions because it replaces petroleum-based monoethylene glycol (MEG), together with terephtalic...

500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....

Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

Forbion raises €1.35bn across two funds
Both funds, the early stage Forbion Ventures Fund VI (€750m) and the Forbion Growth Opportunities Fund II (€600m), which will invest up to €70m in up...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...